Tissue Regenix Group PLC Half Year Trading Update and Notice of Results (8796S)
July 19 2022 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 8796S
Tissue Regenix Group PLC
19 July 2022
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Half Year Trading Update and Notice of Results
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, provides an unaudited trading update for the six months
ended 30 June 2022 (the "Period").
The Group reports that trading in the first half of 2022
continues to be strong and in line with the Board's expectations,
as healthcare markets in the United States begin the return to
pre-pandemic levels. Group revenues for the Period are expected to
be approximately $11.8 million, a 25% increase (27% in constant
currency) on the prior year. The Board remains confident that the
Group is on track to meet its expectations for the full year.
During the first six months of 2022, the BioRinse(R) segment
continued its robust growth and the commercial reorganization of
the dCELL(R) segment began to show benefits as it returned to
growth in the period.
The Group's cash position remains sufficient to support current
business growth plans.
Daniel Lee, Chief Executive Officer, Tissue Regenix, commented :
" The focus on executing our 4S strategy has resulted in a
continued positive trajectory for the Group, despite the lingering
impacts of COVID-19 during the first half of 2022. We are pleased
with the continued growth of our BioRinse business and how our
dCELL business has responded to the commercial reorganization. We
continue to be optimistic in delivering the financial performance
anticipated by our Board for the second half of 2022."
Notice of Results
The Group will publish its interim results on Wednesday 7
September 2022.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. The person responsible
for release of this announcement on behalf of the Company is David
Cocke (Chief Financial Officer).
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Tel: +44(0)20 7710 7600
Adviser and Broker)
Ben Maddison / Nick Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, dental, and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTBLGDRGSBDGDI
(END) Dow Jones Newswires
July 19, 2022 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024